Planning a Regenerative Medicine Trip to Mérida, Mexico

Traveling internationally for regenerative medicine requires more planning than an ordinary vacation. Patients need to think about the medical treatment itself, but also transportation, accommodations, medications, recovery time, follow-up care, and what will happen if an unexpected medical issue occurs.

Mérida, the capital of Yucatán, has become increasingly attractive to international patients because it combines a major city, healthcare services, an international airport, hotels, restaurants, and access to the cultural attractions of the Yucatán Peninsula.

For patients considering stem cell therapy, PRP, exosomes, or other regenerative treatments in Mérida, preparing before the trip can make the experience significantly easier.

Start With a Medical Evaluation Before Booking Your Flight

The first step should be determining whether the proposed treatment is medically appropriate.

A regenerative medicine clinic should normally review relevant medical information before asking a patient to travel. Depending on the condition, this might include medical history, current medications, previous surgeries, laboratory results, X-rays, MRI studies, CT scans, physician reports, or previous treatment records.

Patients should understand what treatment is being proposed, why it is being recommended, and what realistic outcomes can be expected.

International travel should not substitute for proper medical screening.

Understand Exactly What Treatment You Are Receiving

Terms such as "stem cell therapy" can describe very different products and procedures.

Before traveling, patients should know whether they will receive mesenchymal stromal/stem cells, PRP, exosomes, peptides, IV therapy, or some combination of treatments.

For cellular therapies, important questions include the cell source, processing method, viable cell count, sterility testing, laboratory origin, route of administration, and why a particular protocol was selected.

Patients should also understand which parts of a treatment protocol are supported by stronger clinical evidence and which remain investigational.

Verify the Clinic and Laboratory

Mexico regulates establishments involved in regenerative medicine and the handling of human cells and tissues through COFEPRIS.

Current COFEPRIS requirements specifically include sanitary licensing for regenerative medicine establishments as well as facilities involved in collecting, analyzing, preserving, preparing, supplying, or banking cells and tissues. The regenerative-medicine licensing process also addresses matters such as cell traceability, qualified healthcare personnel, facilities, procedures, and collaboration with licensed stem-cell banks. (Gobierno de México)

Patients should therefore evaluate both the clinic providing the treatment and, when applicable, the laboratory or cell bank supplying the biological product.

A facility's authorization should not, however, be interpreted as proof that every treatment offered has been clinically proven for every disease.

Traveling to Mérida

Mérida is served by Mérida International Airport, commonly identified by the airport code MID.

Official airport information currently lists ground-transportation options that include authorized taxi services, ADO transportation, and several rental-car companies. (ASUR)

International patients may find it easier to arrange airport transportation with their clinic, hotel, or a reputable transportation company before arrival, particularly when traveling immediately before or after a medical procedure.

How Long Should You Stay?

The appropriate length of stay depends on the treatment.

A simple orthopedic injection may require much less time than a multi-day regenerative medicine program involving medical evaluation, laboratory testing, IV therapies, rehabilitation, or multiple procedures.

Patients should ask their clinic how many days they recommend staying before purchasing nonrefundable airline tickets.

It may also be useful to leave some flexibility in the travel schedule in case the physician recommends additional observation or changes the treatment plan after the in-person evaluation.

Choose Accommodations for Recovery, Not Just Tourism

A beautiful hotel is useful, but comfort after treatment may be more important than resort amenities.

For patients with mobility limitations, joint problems, neurological conditions, fatigue, or chronic illness, consider accessibility, elevators, walk-in showers, quiet rooms, nearby food, transportation, and the distance from the clinic.

Patients undergoing orthopedic procedures may also want to avoid accommodations that require climbing stairs or walking long distances.

Bring Your Medical Information

International patients should travel with organized medical information.

A useful travel file can include:

Digital copies stored securely on a phone or cloud account can provide an additional backup.

Discuss Medications Before Traveling

Patients should not automatically stop medications because they are receiving regenerative therapy.

Some medications, anticoagulants, anti-inflammatory drugs, immunosuppressive treatments, supplements, or other therapies may affect a procedure or require special instructions.

Any medication changes should be discussed with the treating physician.

Patients should also bring enough of their regular prescription medications for the entire trip, preferably in their original labeled containers.

Plan for the First 24–48 Hours After Treatment

Even when a regenerative procedure is minimally invasive, patients may experience temporary soreness, fatigue, swelling, stiffness, or discomfort.

Planning a demanding sightseeing itinerary immediately after treatment may therefore not be ideal.

A better approach is often to schedule medical treatment first and leave optional tourism for later in the trip, depending on how the patient feels and what the physician recommends.

Traveling With a Companion

Some patients can travel independently, while others may benefit from bringing a spouse, family member, or friend.

A companion can help with transportation, luggage, medications, communication, meals, and mobility after treatment.

This may be particularly valuable for older patients, patients undergoing orthopedic procedures, or individuals receiving more complex treatment programs.

Safety in Mérida and Yucatán

Travel conditions should always be checked immediately before departure because advisories can change.

As of the current U.S. Department of State advisory, Mexico overall is listed at Level 2, "Exercise Increased Caution," while the state of Yucatán is specifically listed at Level 1, "Exercise Normal Precautions." The State Department also recommends reviewing current travel guidance and considering travel insurance that includes medical care and evacuation coverage. (Travel.state.gov)

Patients should still use normal precautions, arrange reliable transportation, protect passports and valuables, and remain aware of their surroundings.

Medical and Travel Insurance

Standard health insurance may not cover elective regenerative medicine performed internationally.

Patients should ask their insurer what is covered before traveling.

Travel insurance may also provide protection for issues unrelated to the procedure, including flight interruptions, lost luggage, illness, emergency hospitalization, or medical evacuation.

Read policy exclusions carefully, because some travel insurance policies exclude complications associated with planned medical procedures.

Ask About Emergency Planning

Before treatment, patients should know what happens if a complication occurs.

Ask who is available after hours, what symptoms require immediate medical attention, where the nearest appropriate hospital is located, and who should be contacted after returning home.

A responsible medical program should have a clear plan for both routine follow-up and unexpected complications.

Plan Your Follow-Up Before Leaving Mexico

Regenerative medicine often involves outcomes that develop over weeks or months rather than immediately.

Before returning home, patients should know when follow-up consultations will occur, whether they will be conducted by video or telephone, what laboratory tests or imaging may be needed, and how progress will be measured.

Patients should also understand whether rehabilitation, physical therapy, nutrition, exercise, or other supportive care is part of the treatment plan.

Enjoy Mérida — But Remember Why You Came

Mérida and the surrounding Yucatán region offer historic architecture, Mayan archaeological sites, cenotes, regional cuisine, haciendas, museums, and cultural attractions. The official Yucatán tourism portal highlights Mérida along with destinations such as Uxmal, Valladolid, the Yucatán coast, and the state's Pueblos Mágicos. (Yucatan.Travel)

For medical travelers, these experiences can make the trip much more enjoyable, but activities should be adjusted according to the procedure performed and the physician's recovery recommendations.

The Bottom Line

Planning a regenerative medicine trip to Mérida involves more than choosing a clinic and purchasing an airline ticket.

Patients should understand the proposed treatment, verify the medical provider and biological product, organize medical records, arrange appropriate transportation and accommodations, plan recovery time, understand potential risks, and establish follow-up care before traveling home.

Mérida can provide an attractive setting for international medical travel, but the quality of the medical decision should remain the first priority.

A well-planned regenerative medicine trip should combine responsible medical evaluation, realistic expectations, clear communication, safe travel arrangements, and enough time to recover comfortably before returning home.

Suggested SEO title:

Planning a Regenerative Medicine Trip to Mérida, Mexico

Suggested meta description:

Planning stem cell or regenerative medicine treatment in Mérida, Mexico? Learn what to know about clinics, COFEPRIS, travel, accommodations, medical records, recovery, safety, and follow-up care.

What Are Mesenchymal Stem Cells? Clinical Uses and Limitations

Mesenchymal stem cells are among the most widely discussed cell types in regenerative medicine. They are being studied for conditions involving inflammation, immune dysfunction, joint degeneration, tissue injury, and impaired healing.

However, the term “mesenchymal stem cells” is often used too broadly in marketing.

In scientific literature, these cells are increasingly referred to as mesenchymal stromal cells, or MSCs. Although they can differentiate into several cell types under laboratory conditions, much of their potential therapeutic activity appears to come from the signals they release and the way they interact with surrounding immune and tissue cells. (PubMed)

Understanding what MSCs can — and cannot — currently do is important for patients considering regenerative medicine.

What Are Mesenchymal Stem Cells?

MSCs are multipotent stromal cells that can be isolated from several tissues in the human body.

Common sources include:

These cells can be expanded in laboratory culture and have biological characteristics that make them interesting for regenerative medicine.

Historically, MSCs attracted attention because they could differentiate into bone, cartilage, and fat cells under laboratory conditions.

Today, researchers increasingly believe that many of their potential therapeutic effects come instead from biological signaling.

MSCs release growth factors, cytokines, extracellular vesicles, and other molecules capable of influencing surrounding cells. They may also affect inflammatory pathways, immune responses, tissue repair, and cellular communication. (PubMed)

Why Are They Called Both “Stem Cells” and “Stromal Cells”?

The terminology can be confusing.

“Mesenchymal stem cells” became the popular term because these cells can demonstrate multipotent differentiation in laboratory environments.

However, not every MSC used clinically behaves like a classical stem cell capable of rebuilding complete tissues.

For this reason, many researchers prefer the term:

Mesenchymal Stromal Cells

Both terms are commonly abbreviated as MSCs.

For patients, the important point is that MSC therapy should not automatically be interpreted as injecting cells that will simply transform into new organs, cartilage, nerves, or other damaged tissue.

How May MSCs Work?

Current research suggests that MSCs may act through several mechanisms.

These include:

Immunomodulation

MSCs can interact with immune cells such as T cells, B cells, macrophages, and dendritic cells.

Researchers are investigating whether these interactions can reduce excessive inflammatory activity in certain diseases.

Paracrine Signaling

MSCs release signaling molecules into their surrounding environment.

These signals may influence:

Extracellular Vesicles and Exosomes

MSCs also release extracellular vesicles containing proteins, lipids, RNA, and other signaling molecules.

This is one reason exosomes and MSCs are frequently discussed together, although exosomes are not themselves stem cells.

Tissue Support

MSCs may help create biological conditions that support repair rather than directly replacing every damaged cell.

These mechanisms are still being actively studied, and their relative importance can differ depending on the disease, tissue, cell source, dose, and method of administration. (PubMed)

Are MSCs Already Used Clinically?

Yes — but clinical use depends heavily on the indication and country.

An important milestone occurred in December 2024 when the U.S. FDA approved Ryoncil (remestemcel-L-rknd), an allogeneic bone-marrow-derived MSC therapy for steroid-refractory acute graft-versus-host disease in pediatric patients two months of age and older.

It became the first FDA-approved mesenchymal stromal cell therapy. (U.S. Food and Drug Administration)

That approval demonstrates that MSC-based therapy can become an established treatment when a specific product, manufacturing process, dose, population, and indication have been sufficiently evaluated.

It does not mean that MSC products are automatically approved or proven for every disease.

MSCs and Osteoarthritis

One of the most heavily studied areas for MSC therapy is knee osteoarthritis.

Multiple randomized controlled trials have investigated intra-articular MSC injections for pain and functional impairment.

A systematic review involving 25 randomized trials and more than 1,000 participants found that MSC therapy may improve pain compared with some control treatments, although the certainty of evidence remained limited because studies differed significantly in methodology, cell products, and treatment protocols. (PubMed)

More recent analyses have continued to report potential improvements in pain and function, while also emphasizing substantial variability among cell sources, doses, processing techniques, and patient populations. (PubMed)

This is important because improvement in symptoms does not necessarily prove that cartilage has been completely regenerated.

Can MSCs Regrow Cartilage?

This is one of the most common claims associated with stem cell clinics.

The evidence does not currently support guaranteeing that MSC injections will rebuild a severely damaged knee or recreate normal cartilage.

Some studies show changes in imaging or biological markers, while others primarily show improvements in pain and function.

Therefore, statements such as:

“Stem cells will regrow your cartilage”

or

“Stem cells will reverse bone-on-bone arthritis”

go beyond what current clinical evidence can reliably guarantee.

MSCs and Crohn’s Disease

MSC therapy has also been studied in Crohn's disease.

One of the more developed applications involves local injection of MSCs into complex perianal fistulas.

A systematic review and meta-analysis of 25 prospective studies involving 596 patients reported meaningful rates of combined remission after local MSC treatment. (PubMed)

Randomized-trial meta-analysis has also shown higher healing rates compared with control treatment in perianal Crohn's disease. (PubMed)

However, this evidence should not be interpreted to mean that intravenous MSC treatment has been proven to cure systemic Crohn's disease.

Local fistula treatment and systemic immune-mediated disease are different clinical questions.

MSCs and Autoimmune Diseases

MSCs are being investigated for several immune-mediated conditions because of their potential immunomodulatory properties.

Research includes conditions such as:

Results vary considerably depending on the disease and protocol.

The potential is scientifically interesting, but MSC therapy remains investigational for many autoimmune indications.

Patients should therefore look for disease-specific clinical evidence rather than assuming that an anti-inflammatory mechanism means the treatment works equally well for every autoimmune condition.

MSCs and Graft-Versus-Host Disease

Graft-versus-host disease is one of the areas where MSCs have been studied most extensively.

MSC therapy has been investigated particularly for patients with acute GVHD that does not respond adequately to corticosteroids. (PubMed)

The FDA approval of Ryoncil for pediatric steroid-refractory acute GVHD represents the clearest example of MSC therapy progressing from experimental research into an approved cell-based treatment. (U.S. Food and Drug Administration)

Does the Source of MSCs Matter?

Potentially, yes.

MSCs obtained from different tissues are not biologically identical.

Bone marrow, adipose tissue, umbilical-cord tissue, and placental tissue can produce cell populations with different growth characteristics and signaling profiles.

Other important variables include:

These differences help explain why two products both marketed as “100 million MSCs” may not necessarily be equivalent.

Is a Larger Cell Dose Better?

Not automatically.

There is currently no universal MSC dose that is optimal for every disease.

Researchers continue to investigate dose-response relationships.

A 2025 systematic review of bone-marrow-derived MSCs for osteoarthritis found that dose remains an important research question rather than a settled standard. (PubMed)

More cells are not necessarily better if the product has poor viability, inadequate characterization, contamination, inappropriate processing, or no evidence supporting the selected dose.

Patients should ask why a particular dose was chosen rather than simply comparing clinics based on the largest advertised cell number.

Autologous vs. Allogeneic MSCs

MSC therapies can be autologous or allogeneic.

Autologous MSCs come from the patient's own tissue.

Allogeneic MSCs come from a donor.

Each approach has advantages and disadvantages.

Autologous cells avoid donor-related immunological considerations but require tissue collection and processing.

Allogeneic products can potentially be prepared and standardized in advance but require careful donor screening, manufacturing controls, storage, and quality testing.

The appropriate approach depends on the specific indication and product.

What Are the Major Limitations of MSC Therapy?

Despite extensive research, MSC therapy still faces several important challenges.

Product Variability

MSC products can differ substantially between laboratories.

Cell source, donor characteristics, processing, expansion, storage, and testing can all affect the final biological product. (PubMed)

Lack of Standardized Dosing

There is no universal cell dose applicable to all diseases.

Different Routes of Administration

MSCs may be administered intravenously, intra-articularly, locally into tissue, or through other routes.

The route used can influence where cells travel and how they interact with the body.

Inconsistent Clinical Trials

Many MSC studies use different endpoints, patient populations, cell sources, and treatment protocols.

This makes direct comparison difficult.

Limited Long-Term Data

Some studies follow patients for only several months.

More long-term data are needed for many applications.

Mechanisms Are Still Being Studied

Researchers understand many aspects of MSC signaling, but their biological behavior remains complex.

What Are the Potential Risks?

MSC therapy is often marketed as completely safe because the cells are described as “natural.”

That description can be misleading.

Cell-based treatments can involve risks related to:

The FDA has warned patients about serious adverse events linked to improperly marketed regenerative medicine products, including infections and other complications. (U.S. Food and Drug Administration)

Safety therefore depends not only on the type of cell but also on manufacturing, sterility, physician oversight, patient selection, and administration.

MSC Therapy in Mexico

Mexico has specific regulatory pathways for establishments involved in regenerative medicine.

COFEPRIS currently lists sanitary-license categories for regenerative medicine establishments, stem-cell collection centers, stem-cell banks, and healthcare establishments involved in extracting, analyzing, preserving, preparing, or supplying human cells and tissues. (Gobierno de México)

The COFEPRIS regenerative-medicine licensing process specifically applies to centers carrying out activities involving the obtaining, processing, preservation, or application of progenitor or stem cells, tissues, and cells. (Gobierno de México)

However, regulatory authorization of a facility should not be confused with scientific proof that every MSC therapy offered by that facility is effective for every medical condition.

Questions Patients Should Ask

Before considering MSC therapy, patients should ask:

Beware of One-Size-Fits-All Stem Cell Claims

The International Society for Stem Cell Research specifically cautions patients about clinics marketing the same stem cell treatment for many unrelated diseases.

Different medical conditions involve different biological mechanisms and therefore require different treatment strategies. (ISSCR)

A clinic claiming that one MSC infusion can reliably treat arthritis, autism, Alzheimer's disease, Crohn's disease, spinal cord injury, diabetes, Parkinson's disease, and dozens of other unrelated conditions should be evaluated very carefully.

The Bottom Line

Mesenchymal stromal cells represent one of the most important areas of modern regenerative medicine research.

Their potential effects appear to involve much more than simply becoming new tissue. Immunomodulation, paracrine signaling, extracellular vesicles, and interactions with surrounding cells may all contribute to their biological activity.

There are now specific situations in which MSC-based therapy has reached clinical approval, including the FDA-approved use of Ryoncil for pediatric steroid-refractory acute graft-versus-host disease. (U.S. Food and Drug Administration)

Other applications — including osteoarthritis, autoimmune diseases, neurological conditions, and systemic regenerative treatments — remain at different stages of clinical investigation.

The most important question is therefore not simply:

“Do stem cells work?”

A better question is:

“What specific MSC product, for what disease, at what dose, using what route, supported by what evidence?”

That distinction separates serious regenerative medicine from overly broad stem cell marketing.

Stem Cell Therapy for Knee Osteoarthritis: What Patients Should Know

Knee osteoarthritis is one of the most common causes of chronic knee pain, stiffness, and reduced mobility. As cartilage wears down and the joint becomes inflamed, everyday activities such as walking, climbing stairs, exercising, or standing for long periods can become more difficult.

Because conventional treatments do not always provide enough relief, interest in regenerative medicine — especially mesenchymal stromal/stem cell therapy — has increased significantly.

But what does the current evidence actually show?

What Is Knee Osteoarthritis?

Knee osteoarthritis is a degenerative joint condition involving changes in cartilage, bone, synovial tissue, and other structures within the knee.

Common symptoms include:

Treatment usually begins with approaches such as weight management, physical therapy, exercise, anti-inflammatory medications, injections, and other non-surgical therapies.

For advanced disease, knee replacement may eventually be considered.

What Is Stem Cell Therapy for Knee Osteoarthritis?

Most regenerative treatments marketed as “stem cell therapy” for knee osteoarthritis involve mesenchymal stromal cells, commonly called MSCs.

These cells may come from sources such as:

Rather than simply transforming into new cartilage, much of the current scientific interest focuses on the signaling molecules released by MSCs.

These signals may influence:

This means MSC therapy should not be described simply as “injecting new cartilage cells into the knee.”

What Does the Current Research Show?

Recent randomized controlled trials and systematic reviews suggest that intra-articular MSC therapy may reduce pain and improve function in some patients with knee osteoarthritis.

A 2025 meta-analysis of randomized controlled trials found improvements in pain and functional outcomes after MSC injections compared with control treatments. (PubMed)

Another systematic review of 25 randomized trials involving more than 1,000 patients found improvements in pain scores compared with viscosupplementation, although the authors emphasized that stronger evidence is still needed because studies vary substantially in cell source, dose, preparation, and treatment protocols. (PubMed)

A newer 2026 meta-analysis of 28 randomized trials also found improvements in several pain and functional measures. However, MRI outcomes did not show consistent structural improvement, meaning symptom improvement should not automatically be interpreted as proven cartilage regeneration. (PubMed)

Can Stem Cells Regrow Knee Cartilage?

This is one of the most important questions patients ask.

At this time, there is not enough consistent clinical evidence to say that stem cell injections reliably regenerate substantial amounts of damaged knee cartilage.

Some studies have reported changes on MRI or biological markers, but structural results remain inconsistent.

The strongest current evidence is more supportive of potential improvements in:

rather than guaranteed restoration of cartilage.

Clinics claiming that a stem cell injection will definitely “regrow your knee” or reverse severe arthritis should be approached cautiously.

Who May Be a Candidate?

Potential candidates may include patients with mild to moderate knee osteoarthritis who continue to have symptoms despite conservative treatment.

Factors physicians may consider include:

Stem cell therapy may be less likely to provide meaningful benefit in patients with severe joint destruction, major deformity, or advanced bone-on-bone disease.

A proper orthopedic evaluation is important before deciding whether regenerative treatment is reasonable.

Does Cell Source Matter?

Possibly.

Studies use different types of MSC preparations, including cells derived from bone marrow, adipose tissue, and donor tissues.

These products are not automatically equivalent.

Researchers are still investigating how factors such as:

affect outcomes.

A 2026 review found that outcomes varied depending on preparation and treatment characteristics, illustrating why simply comparing clinics by advertised “cell count” can be misleading. (PubMed)

Is More Stem Cells Always Better?

No.

There is no universally established dose that is best for every patient with knee osteoarthritis.

Some studies use relatively modest doses, while others use much larger numbers of cells.

The quality and biological characteristics of the cells may matter as much as — or more than — the advertised number.

Patients should ask:

Single Injection or Multiple Treatments?

Research has examined both single and repeated MSC injections.

A 2025 network meta-analysis suggested that repeated injections may produce greater improvements in pain and function at some follow-up periods, but repeated treatments were also associated with more adverse events. (PubMed)

This does not mean that multiple injections are automatically better.

Treatment frequency should be based on clinical evidence and individualized assessment rather than simply assuming that more treatment produces better results.

What Are the Possible Risks?

Reported adverse effects in clinical studies are often relatively mild, such as temporary:

However, regenerative treatments can also carry more serious risks if products are improperly collected, processed, stored, transported, or administered.

Potential concerns include:

The FDA has warned that regenerative products marketed for orthopedic conditions can carry significant risks when used outside appropriate regulatory pathways. (U.S. Food and Drug Administration)

Is Stem Cell Therapy FDA Approved for Knee Osteoarthritis?

No.

The FDA states that regenerative medicine products marketed as stem cell therapies are not FDA-approved for orthopedic conditions such as knee osteoarthritis in the United States. (U.S. Food and Drug Administration)

This does not mean research has stopped.

Numerous clinical trials continue to investigate MSC therapies for knee osteoarthritis, but patients should understand the difference between an investigational treatment and an FDA-approved therapy.

What About Stem Cell Therapy in Mexico?

Mexico has its own regulatory system.

COFEPRIS regulates healthcare establishments involved in regenerative medicine, cell collection, cell banking, and the processing or supply of human cells and tissues.

In 2026, COFEPRIS continued to list specific sanitary-license categories for regenerative medicine establishments and facilities involved in extracting, analyzing, preserving, preparing, or supplying human cells and tissues. (Gobierno de México)

Patients considering treatment in Mexico should evaluate both the clinic and the laboratory supplying the cells.

Stem Cells vs. PRP for Knee Osteoarthritis

PRP and MSC therapy are different treatments.

PRP uses concentrated platelets from the patient's own blood.

MSC therapy involves living stromal cells that may influence inflammatory and regenerative signaling.

Both have been studied for knee osteoarthritis.

PRP currently has a longer clinical history in orthopedic medicine, while MSC therapy represents a more complex biological intervention with growing but less standardized evidence.

The best option depends on the patient, disease severity, previous treatments, and medical evaluation.

Questions Patients Should Ask

Before considering stem cell therapy for knee osteoarthritis, ask:

The Bottom Line

Stem cell therapy for knee osteoarthritis is an active and increasingly studied area of regenerative medicine.

Recent randomized trials and meta-analyses suggest that MSC-based injections may improve pain and function for some patients, particularly over several months of follow-up. (PubMed)

However, the evidence does not support guaranteeing cartilage regeneration, reversing advanced arthritis, or avoiding knee replacement in every patient.

Results vary because knee osteoarthritis itself varies — and so do cell sources, doses, processing methods, and patient characteristics.

Patients should approach stem cell therapy as a medical treatment requiring careful evaluation, transparent discussion of evidence, and realistic expectations rather than as a guaranteed cure.

Suggested meta title:

Stem Cell Therapy for Knee Osteoarthritis | What Patients Should Know

Suggested meta description:

Learn what current research shows about stem cell therapy for knee osteoarthritis, including MSC treatments, pain and function outcomes, cartilage regeneration, risks, patient selection, and treatment in Mexico.

Stem Cell Therapy in Mexico for Autoimmune Diseases: Current Evidence and Regenerative Approaches

Autoimmune diseases occur when the immune system mistakenly attacks the body's own tissues. Conditions such as multiple sclerosis, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and Crohn's disease can involve chronic inflammation, periods of relapse and remission, and progressive tissue damage.

Interest in stem cell therapy for autoimmune diseases has grown because certain cell-based treatments may influence immune regulation rather than simply treating individual symptoms.

However, “stem cell therapy” can refer to very different procedures, and the evidence is much stronger for some autoimmune diseases than for others.

For patients considering stem cell therapy in Mexico, understanding these differences is essential.

Why Are Stem Cells Being Studied for Autoimmune Disease?

Most regenerative clinics discussing stem cells for autoimmune disorders are referring to mesenchymal stromal cells, commonly called MSCs.

MSCs have attracted attention because they release signaling molecules capable of interacting with several parts of the immune system.

Research suggests MSCs can influence:

Rather than simply replacing damaged cells, much of the therapeutic interest in MSCs involves their immunomodulatory and paracrine effects.

This does not mean MSCs have been proven to “reset” or cure the immune system.

A 2025 systematic review and meta-analysis covering 42 randomized controlled trials and 2,183 participants found potentially beneficial effects in several immune-mediated conditions, particularly systemic lupus erythematosus and inflammatory bowel disease, while results were less convincing for multiple sclerosis and systemic sclerosis. The authors also emphasized the need for additional research. (PubMed)

MSC Therapy and Hematopoietic Stem Cell Transplantation Are Not the Same

This distinction is extremely important.

Mesenchymal stromal cell therapy typically involves administering MSCs derived from tissues such as bone marrow, adipose tissue, or perinatal tissue.

Autologous hematopoietic stem cell transplantation, or AHSCT, is a very different procedure.

AHSCT usually involves:

The goal is closer to immune-system reconstitution than tissue regeneration.

AHSCT is substantially more intensive and carries risks that are very different from those associated with an MSC infusion.

Patients should therefore be cautious when clinics simply use the phrase “stem cell therapy” without identifying exactly which treatment they mean.

Multiple Sclerosis

Multiple sclerosis is one of the autoimmune diseases in which stem-cell-based approaches have received significant research attention.

For highly active relapsing-remitting multiple sclerosis, the strongest evidence currently relates to AHSCT rather than ordinary MSC infusions.

Research suggests AHSCT can substantially suppress inflammatory disease activity in carefully selected patients with active relapsing MS. A 2025 comparative study found lower relapse rates and greater likelihood of disability improvement with AHSCT compared with some immune-reconstitution therapies, although delayed complications — mainly infections — occurred in a substantial proportion of transplant recipients. (PubMed)

MSC therapy for multiple sclerosis is also being investigated, but the evidence is less established. The 2025 randomized-trial meta-analysis did not find consistent improvement across major MS outcomes with MSC therapy. (PubMed)

This is an important example of why different types of “stem cell treatment” should not be grouped together.

Systemic Lupus Erythematosus

Systemic lupus erythematosus, or SLE, is a complex autoimmune disease that may affect the joints, skin, kidneys, nervous system, cardiovascular system, and other organs.

MSCs are being studied because of their potential effects on immune regulation and inflammatory signaling.

The 2025 meta-analysis of randomized studies found improvement in SLE disease-activity scores among patients receiving MSC therapy. (PubMed)

Early human research is continuing. A phase 1 study published in 2025 evaluated allogeneic umbilical-cord-derived MSCs in patients with SLE, reflecting ongoing interest in this treatment strategy. (PubMed)

However, MSC therapy is not currently a replacement for established lupus treatments such as corticosteroids, immunosuppressive medications, or biologic therapies.

The evidence remains promising but developing.

Rheumatoid Arthritis

Rheumatoid arthritis is an autoimmune inflammatory disease primarily affecting the joints.

MSC research has focused on whether the cells' immunomodulatory effects could reduce inflammatory activity in patients who continue to have active disease despite conventional treatment.

A systematic review and meta-analysis of clinical studies reported improvement in measures such as disease activity and inflammatory markers, but the evidence base was small and benefits were not consistently sustained over longer follow-up. (PubMed)

At present, MSC therapy should therefore be considered investigational for rheumatoid arthritis.

Established disease-modifying antirheumatic drugs and biologic therapies remain the foundation of treatment.

Crohn's Disease

Crohn's disease is an immune-mediated inflammatory bowel disease.

Stem-cell research in Crohn's disease deserves special attention because evidence differs significantly depending on the manifestation being treated.

Some of the strongest clinical evidence for MSC therapy involves complex perianal fistulas associated with Crohn's disease.

A recent network meta-analysis involving 15 randomized controlled trials and 2,475 patients found that MSC treatment improved fistula remission and fistula response compared with placebo. (PubMed)

A broader umbrella review of systematic reviews also reported improvements in fistula healing and some remission outcomes. (PubMed)

However, evidence for local treatment of perianal fistulas should not automatically be interpreted as proof that intravenous MSC therapy can eliminate systemic Crohn's disease.

Those are very different claims.

Systemic Sclerosis

Systemic sclerosis, or scleroderma, can cause severe fibrosis involving the skin and internal organs, particularly the lungs.

Among autoimmune diseases, systemic sclerosis has some of the strongest clinical evidence supporting carefully selected use of AHSCT.

Clinical studies have shown that AHSCT can improve skin involvement, lung function, and survival in selected patients with severe progressive systemic sclerosis.

However, the procedure carries significant short-term risks because of the intensive conditioning required.

Recent reviews continue to support AHSCT as a potentially powerful option for carefully selected severe cases while emphasizing patient selection, treatment-center experience, and transplant-related risks. (PubMed)

The evidence for ordinary MSC infusion in systemic sclerosis is considerably less established.

Can Stem Cells “Reset” the Immune System?

This phrase needs to be used carefully.

AHSCT can produce profound immune reconstitution because the patient's immune system is intentionally suppressed before hematopoietic stem cells are reinfused.

MSC therapy works differently.

MSCs appear primarily to modify immune signaling through paracrine and immunomodulatory mechanisms.

Calling an MSC infusion an “immune-system reset” may therefore overstate what has been demonstrated clinically.

A more accurate description is that MSCs are being investigated for their ability to modulate abnormal inflammatory and immune responses.

What About Exosomes?

Exosomes are sometimes included in autoimmune regenerative programs.

Exosomes are microscopic extracellular vesicles released by cells and can carry proteins, lipids, RNA, and signaling molecules.

They are not stem cells.

Because MSCs produce extracellular vesicles, researchers are studying whether some of the immunomodulatory effects attributed to MSCs might eventually be reproduced using cell-free therapies.

Clinical evidence for exosome treatment of autoimmune diseases, however, remains much less developed than the evidence for MSCs.

The FDA currently states that there are no FDA-approved exosome products in the United States. (U.S. Food and Drug Administration)

Does Cell Source Matter?

Potentially.

MSCs can be obtained from:

These products should not automatically be considered interchangeable.

Differences can include:

Research in lupus, for example, suggests that MSC source and manufacturing characteristics may influence biological behavior and clinical outcomes. (PubMed)

Patients should therefore evaluate more than the number of cells advertised by a clinic.

Is a Higher Cell Dose Better?

Not necessarily.

There is currently no universal MSC dose established for autoimmune diseases.

More cells do not automatically produce a stronger therapeutic effect.

The appropriate dose may depend on:

Extremely large advertised cell numbers should not be interpreted by themselves as evidence of a superior treatment.

Stem Cell Therapy in Mexico

Mexico has a regulatory framework for healthcare establishments involved in regenerative medicine and human cells and tissues.

COFEPRIS currently identifies specific sanitary-license categories for regenerative medicine establishments, stem-cell collection centers, stem-cell banks, and facilities involved in extracting, analyzing, preserving, preparing, or supplying human cells and tissues. (Gobierno de México)

COFEPRIS also maintains listings of authorized establishments involving stem cells and regenerative medicine. (Gobierno de México)

However, regulatory authorization of a clinic or laboratory should not be confused with scientific proof that a particular treatment works for a specific autoimmune disease.

Patients need to evaluate both questions separately:

Is the treatment being provided within the applicable regulatory framework?

And:

What scientific evidence supports using that treatment for this specific disease?

What Should Patients Ask Before Treatment?

Patients considering regenerative medicine for an autoimmune disease should ask about:

Patients should be especially cautious of clinics claiming that one stem cell treatment can cure dozens of unrelated autoimmune, neurological, orthopedic, and metabolic diseases.

Stem Cells Should Not Automatically Replace Standard Treatment

Conventional autoimmune therapies have improved significantly.

Depending on the disease, established treatments may include:

Regenerative medicine may eventually become part of treatment for more autoimmune diseases, but patients should not discontinue proven therapy simply because they are receiving stem cells.

Any changes should be coordinated with appropriate medical specialists.

What Does the Current Evidence Really Say?

The evidence is not simply “stem cells work” or “stem cells do not work.”

It depends heavily on the disease and the type of cell therapy.

Currently:

The International Society for Stem Cell Research continues to emphasize that many stem-cell interventions marketed directly to patients remain unproven and that treatments should be evaluated according to the quality of clinical evidence and regulatory oversight. (ISSCR)

The Bottom Line

Stem cell therapy represents one of the most interesting areas of research in autoimmune medicine, but different diseases — and different stem cell technologies — have very different levels of evidence.

Mesenchymal stromal cells are being studied primarily for their potential ability to regulate inflammatory and immune signaling.

Hematopoietic stem cell transplantation takes a much more intensive approach aimed at immune reconstitution and has established a stronger clinical role in selected severe autoimmune conditions.

For patients considering stem cell therapy in Mexico, the most important questions are not simply how many cells are being offered or whether a clinic uses the latest technology.

The important questions are:

What type of cell therapy is being proposed?

Why is it appropriate for this particular autoimmune disease?

What evidence supports it?

What are the risks?

And how will the patient's response be measured?

Regenerative medicine should be approached as individualized medical care — not as a universal cure for autoimmunity.

Inside NovaCell Wellness Center’s Integrated Regenerative Programs

Regenerative medicine is often presented as a single treatment: a stem cell infusion, a PRP injection, an exosome product, or another isolated procedure.

NovaCell Wellness Center is being designed around a different concept: an integrated regenerative program in which medical evaluation, regenerative therapies, supportive technologies, recovery strategies, and follow-up are organized around the individual patient rather than treated as unrelated services.

The goal is not to simply provide “more treatments.” The goal is to determine which components may reasonably complement one another, which are unnecessary, and which should not be used for a particular patient.

What Does “Integrated Regenerative Medicine” Mean?

An integrated program begins with the understanding that healing and recovery involve more than one biological process.

Inflammation, circulation, immune signaling, cellular metabolism, tissue oxygenation, nutrition, physical function, sleep, and underlying disease can all influence how a patient feels and recovers.

For this reason, NovaCell’s program model brings multiple areas of regenerative and supportive medicine together under one coordinated plan.

Depending on the patient, this may include:

Not every patient needs every therapy.

The treatment plan should be determined by medical history, diagnosis, treatment goals, current medications, previous therapies, laboratory information, imaging when applicable, and the available scientific evidence.

Step One: Medical Evaluation

Before regenerative treatment is considered, the medical team needs to understand what problem is actually being treated.

Evaluation may include:

This step is particularly important for international patients traveling to Mexico.

A regenerative program should not begin simply because a patient requests a certain number of stem cells.

The first question should be:

What is medically appropriate for this patient?

Mesenchymal Stromal/Stem Cell Therapies

Mesenchymal stromal cells, commonly referred to as MSCs, are one of the principal areas of research in regenerative medicine.

Researchers are investigating their potential biological effects on inflammatory signaling, immune regulation, tissue repair, and cell-to-cell communication.

However, stem cell therapy should not be described as a guaranteed method of replacing damaged tissue.

For many conditions being studied today, MSC therapies remain investigational. The International Society for Stem Cell Research emphasizes that most stem-cell interventions marketed for many diseases have not yet established sufficient evidence of safety and effectiveness for routine use. (ISSCR)

NovaCell’s approach is intended to evaluate cellular therapies as one potential part of a broader treatment strategy rather than presenting stem cells as a universal cure.

PRP and Orthopedic Regenerative Medicine

Platelet-rich plasma uses components obtained from the patient's own blood.

After blood is collected and processed, platelet-rich plasma containing concentrated platelets and signaling molecules can be injected into selected areas such as joints, tendons, or other musculoskeletal tissues.

PRP has a longer clinical history than many newer regenerative treatments and has been studied particularly extensively in orthopedic medicine.

Within an integrated program, PRP may be considered independently or alongside rehabilitation, physical therapies, shockwave therapy, light therapy, or other physician-directed interventions depending on the condition.

Exosomes

Exosomes are extracellular vesicles involved in communication between cells.

They are not stem cells.

Researchers are studying exosomes because they can transport proteins, lipids, RNA, and other signaling molecules that may influence surrounding cells.

Interest in exosome-based treatments has grown considerably, but clinical evidence and manufacturing standards remain less mature than many patients realize.

The FDA currently states that there are no FDA-approved exosome products in the United States. (U.S. Food and Drug Administration)

For this reason, exosome-based therapies should be discussed with patients in terms of their investigational status, product source, laboratory controls, and available evidence rather than marketed as proven cures.

Hyperbaric Oxygen Therapy

NovaCell’s integrated model also includes hyperbaric oxygen therapy, or HBOT.

HBOT exposes the patient to oxygen under increased atmospheric pressure.

It is an established medical therapy for specific indications such as decompression sickness, certain difficult wounds, radiation injury, and carbon monoxide poisoning.

Researchers are also investigating HBOT as an adjunctive therapy in other areas involving inflammation, tissue recovery, and musculoskeletal conditions. A recent systematic review found potentially beneficial effects in some musculoskeletal pain conditions, while also emphasizing differences among studies and the need for stronger evidence. (PubMed)

Within an integrated program, HBOT should therefore be viewed as an adjunct when medically appropriate rather than as a replacement for the primary treatment.

Red and Near-Infrared Light Therapy

Photobiomodulation uses specific wavelengths of red and near-infrared light.

Research is examining its effects on cellular energy production, inflammatory signaling, circulation, pain, and tissue recovery.

At NovaCell, red-light therapy is intended primarily as a supportive recovery modality that can be incorporated around other treatments when appropriate.

It is not meant to replace diagnosis, medical treatment, rehabilitation, or necessary surgical care.

Cryotherapy and Recovery

Whole-body or localized cold exposure is often used in sports medicine and wellness programs to support temporary reductions in soreness and perceived inflammation.

NovaCell’s cryotherapy component is designed as part of the recovery side of the program rather than as a regenerative treatment by itself.

This distinction is important.

A therapy can potentially improve comfort or recovery without actually rebuilding tissue.

IV Support

IV therapy may be incorporated when there is a medical reason for hydration, nutrient replacement, or another physician-directed intervention.

The contents of an IV should be selected according to the patient's needs rather than using the same combination for everyone.

Medical screening is particularly important because vitamins, minerals, medications, and other compounds administered intravenously can have contraindications and potential adverse effects.

Peptide-Based Protocols

Peptides are another rapidly developing area of regenerative and metabolic research.

Different peptides have very different mechanisms, evidence levels, regulatory status, and safety profiles.

For that reason, NovaCell’s model treats peptide protocols as physician-directed interventions rather than general wellness supplements.

Some peptides frequently discussed online remain investigational and are not approved treatments for many of the conditions for which they are promoted.

Their use should therefore be evaluated separately from established medications and therapies.

Advanced Blood Processing and Filtration

NovaCell’s broader program concept also includes advanced blood-processing and filtration technologies as potential adjunctive services.

These procedures are distinct from stem cell therapy.

Their evidence base, appropriate applications, risks, and regulatory requirements can also differ significantly.

They should not be presented as “detoxification” treatments capable of removing every inflammatory substance, toxin, infection, or disease process from the body.

Any use should be based on medical evaluation, an appropriate clinical rationale, and applicable regulatory authorization.

Combining Therapies Does Not Automatically Make a Program Better

One of the most important principles behind an integrated program is that more therapy is not necessarily better therapy.

Giving stem cells, exosomes, PRP, peptides, HBOT, IV therapy, cryotherapy, and other treatments simultaneously does not automatically create a superior result.

Some patients may require only one primary intervention.

Others may benefit from carefully selected supportive treatments.

And some patients may not be appropriate candidates for regenerative therapy at all.

The purpose of integration should be coordination — not simply accumulation.

Monitoring Results

A regenerative medicine program should have a way to determine whether treatment is actually helping.

Depending on the condition, monitoring may include:

This is particularly important because regenerative treatments may produce gradual changes rather than immediate results.

Patients should know before treatment how progress will be evaluated.

International Patients

NovaCell Wellness Center is located in Mérida, Yucatán, making international patient coordination an important part of the program design.

A medical trip may involve more than the procedure itself.

Planning can include:

Patients traveling internationally should also understand what care is available if an unexpected complication occurs.

Regulation in Mexico

Regenerative medicine facilities in Mexico operate within a regulatory framework overseen by COFEPRIS.

Current federal licensing categories specifically include regenerative medicine establishments, facilities handling human organs, tissues and cells, stem-cell collection centers, and stem-cell banks. COFEPRIS states that establishments performing these regulated activities require appropriate sanitary authorization before beginning operations. (Gobierno de México)

Importantly, authorization of a healthcare establishment should not be confused with proof that every treatment offered by that establishment is effective for every disease.

Regulatory compliance and clinical evidence remain separate questions.

Transparency Matters

Regenerative medicine is an exciting field, but it is also an area where marketing sometimes moves faster than science.

The FDA and the International Society for Stem Cell Research both warn patients about regenerative products marketed with claims that exceed the available evidence. (U.S. Food and Drug Administration)

A responsible program should therefore be able to explain:

The NovaCell Approach

The concept behind NovaCell Wellness Center is not simply to place multiple technologies inside one building.

The objective is to connect medical evaluation, regenerative medicine, supportive therapies, recovery technologies, and follow-up into one coordinated patient experience.

For one patient, that may mean an orthopedic procedure combined with carefully selected recovery modalities.

For another, the focus may be systemic inflammation, physical recovery, mobility, or general regenerative support.

The treatment plan should change with the patient — not the other way around.

The Bottom Line

Integrated regenerative medicine should not mean giving every available therapy to every patient.

It should mean choosing treatments deliberately.

Stem cells, PRP, exosomes, HBOT, red-light therapy, cryotherapy, IV support, peptides, and other technologies each have different mechanisms, evidence levels, risks, and appropriate uses.

NovaCell Wellness Center’s program model is built around bringing those tools together through individualized medical evaluation, careful treatment selection, coordinated recovery, and follow-up rather than relying on a single procedure or one-size-fits-all protocol.

The objective is not to promise regeneration.

It is to create a more organized, medically supervised approach to regenerative and restorative care.

Understanding Stem Cell Regulations in Mexico

Mexico has become an important destination for regenerative medicine, including stem cell therapies, PRP, exosomes, and other biologic treatments. However, patients should understand that regenerative medicine in Mexico is regulated and that not every clinic, laboratory, or treatment operates under the same authorization.

The principal federal authority responsible for health regulation is COFEPRIS — the Comisión Federal para la Protección contra Riesgos Sanitarios.

Who Regulates Stem Cell Therapy in Mexico?

COFEPRIS regulates healthcare establishments, medical products, laboratories, biologic materials, and activities involving human cells and tissues.

Mexican regulations specifically recognize several types of establishments involved with regenerative medicine, including facilities that:

COFEPRIS states that establishments dedicated to regenerative medicine and those involved in the handling of stem cells require a sanitary license before beginning operations. (Gobierno de México)

What Is a COFEPRIS Sanitary License?

A sanitary license is an authorization allowing a healthcare establishment to perform specified regulated activities.

COFEPRIS currently identifies licensing categories that include:

The current federal framework also includes regenerative medicine within the sanitary licensing process for healthcare establishments. (Gobierno de México)

Importantly, a clinic having a healthcare license does not automatically mean that every treatment it advertises has been independently proven effective or specifically approved for every medical condition.

Licensing of the facility and scientific evidence for a treatment are two different issues.

Regenerative Medicine Establishments

COFEPRIS specifically provides a licensing pathway for regenerative medicine establishments.

According to the federal government, this process applies to centers involved in activities such as obtaining, processing, preserving, or applying progenitor or stem cells, tissues, and cellular materials. (Gobierno de México)

This means regenerative medicine is not simply an unregulated medical category in Mexico.

Facilities performing these activities may fall under specific sanitary requirements depending on exactly what they do.

What About Stem Cell Laboratories?

The laboratory supplying or processing stem cells is an important part of the regulatory picture.

Facilities that perform activities such as:

may require their own appropriate authorization depending on the activities performed.

COFEPRIS specifically lists licensing for establishments involved in the extraction, analysis, conservation, preparation, and supply of human organs, tissues, and cells. (Gobierno de México)

For patients, this means evaluating the clinic alone is not enough.

The origin and processing of the biological product should also be investigated.

Does COFEPRIS Approval Mean Stem Cell Therapy Is Proven?

No.

This is an important distinction.

A regulatory authorization allowing a facility to perform certain activities does not necessarily establish that a particular stem cell treatment has been proven to cure or effectively treat a specific disease.

Scientific evidence varies considerably depending on the condition.

Some regenerative treatments have substantial clinical research behind them, while others remain experimental.

Patients should therefore separate three questions:

Those are related questions, but they are not the same.

What Should Patients Ask a Stem Cell Clinic in Mexico?

Before undergoing treatment, patients should request clear information about:

Patients should also be cautious when a clinic guarantees results or claims that stem cells can cure a long list of unrelated diseases.

Stem Cells vs. PRP vs. Exosomes

Different regenerative therapies can fall under different regulatory and clinical categories.

PRP is usually prepared from the patient's own blood and is biologically different from cultured stem-cell products.

Stem cell therapies involve living cells and may require additional handling, testing, storage, and laboratory controls.

Exosome products are cell-free extracellular vesicle preparations and represent a different category of biologic therapy.

A clinic offering multiple regenerative treatments should be able to explain exactly what each product contains and where it comes from.

Why Regulation Matters for International Patients

Many patients travel to Mexico specifically because regenerative therapies may be available there that are not routinely offered in their home countries.

That makes due diligence especially important.

Patients should not choose a clinic based only on:

Instead, patients should evaluate the complete treatment system: physician oversight, facility authorization, laboratory quality, product documentation, sterility, clinical protocol, and follow-up.

Mexico's Regulatory System Continues to Evolve

Mexico has continued updating and simplifying its healthcare licensing framework.

In 2026, federal procedures consolidated several healthcare licensing categories under an updated sanitary-license process while continuing to recognize regenerative medicine, stem-cell collection, cell banking, and cell-processing activities as regulated healthcare services. (Gobierno de México)

Because regulations and administrative procedures can change, patients and clinics should verify current requirements directly with COFEPRIS rather than relying on older websites or marketing claims.

The Bottom Line

Stem cell therapy in Mexico is not simply an unregulated industry.

COFEPRIS regulates healthcare establishments involved in regenerative medicine, stem cells, tissues, cell processing, and related activities. However, regulatory authorization of an establishment should not be confused with proof that every therapy it offers is effective for every condition.

Patients considering stem cell treatment in Mexico should evaluate both regulatory compliance and scientific evidence.

A responsible regenerative medicine provider should be willing to explain where its cells come from, how they are processed, what testing is performed, who supervises treatment, and what evidence supports the proposed therapy.

Suggested meta title:

Understanding Stem Cell Regulations in Mexico | COFEPRIS Guide

Suggested meta description:

Learn how stem cell therapy is regulated in Mexico, the role of COFEPRIS, sanitary licensing, stem cell laboratories, regenerative medicine facilities, and what patients should verify before treatment.

Regenerative medicine includes several different biological approaches designed to support the body’s natural repair processes. Three of the most commonly discussed options are platelet-rich plasma (PRP), mesenchymal stromal/stem cell therapies, and exosome-based therapies.

Although these treatments are often grouped together, they are not the same. They come from different sources, contain different biological components, and have very different levels of clinical evidence.

Understanding these differences can help patients ask better questions when considering regenerative medicine in Mexico or elsewhere.

What Is PRP?

Platelet-rich plasma, or PRP, is prepared from a patient’s own blood.

A small amount of blood is collected and placed into a centrifuge. The centrifuge separates the blood into different components, allowing clinicians to concentrate the platelets and plasma.

Platelets contain signaling molecules and growth factors involved in wound healing and tissue repair.

Because PRP comes from the patient's own blood, it is considered an autologous treatment.

PRP has been studied extensively in orthopedic and sports-medicine applications, including:

Clinical evidence varies by condition and by the way PRP is prepared. A 2025 systematic review of randomized trials in knee osteoarthritis found modest short-term improvements in pain and function compared with placebo, although benefits were less clear at longer follow-up. (PubMed)

What Are Stem Cells?

When regenerative clinics discuss “stem cell therapy,” they are often referring to mesenchymal stromal cells, commonly called MSCs.

MSCs can be obtained from several tissue sources, including bone marrow, adipose tissue, and perinatal tissues such as umbilical-cord-associated tissue.

Researchers initially focused on the ability of MSCs to differentiate into different cell types. Today, much of their potential therapeutic activity is believed to come from the signals they release into surrounding tissue.

These signals may influence:

Clinical research is especially active in orthopedic conditions such as knee osteoarthritis. Recent meta-analyses of randomized trials suggest that MSC-based treatments may improve pain and function in some patients, but studies remain heterogeneous in cell source, dose, preparation methods, and treatment protocols. Long-term efficacy and safety still require additional research. (PubMed)

It is also important to understand the regulatory distinction. In the United States, the FDA states that the currently approved stem-cell products are blood-forming stem cells used for specific hematologic disorders; stem-cell products marketed for orthopedic, neurological, autoimmune, and many other conditions are not FDA-approved for those indications. (U.S. Food and Drug Administration)

What Are Exosomes?

Exosomes are microscopic extracellular vesicles released by cells.

They are not stem cells.

Instead, exosomes function partly as biological communication packages. They can carry proteins, lipids, RNA, and other signaling molecules from one cell to another.

In regenerative medicine research, many exosome products are derived from cultures of mesenchymal stromal cells.

This is one reason stem cells and exosomes are frequently discussed together: some of the biological effects associated with MSCs appear to occur through extracellular vesicles and other signaling molecules released by the cells.

Researchers are studying exosomes for their possible roles in:

However, exosome therapy is still much earlier in its clinical development than PRP.

Human studies are increasing, but existing trials remain relatively small and highly variable in manufacturing methods, dosing, source material, and administration techniques. Reviews continue to describe exosome-based therapies as promising but experimental. (PubMed)

The FDA currently states that there are no FDA-approved exosome products in the United States. (U.S. Food and Drug Administration)

PRP vs. Stem Cells vs. Exosomes

Is One Treatment Better Than the Others?

Not necessarily.

These therapies work differently, so the appropriate treatment depends on the medical condition, treatment goals, patient health, and quality of the biological product.

PRP may make sense when a relatively simple autologous therapy is appropriate.

MSC therapy involves living cells and may provide a broader biological signaling environment.

Exosomes offer a cell-free approach intended to deliver signaling molecules without administering living cells, but clinical evidence remains less mature.

The idea that one regenerative treatment is automatically “stronger” than another is overly simplistic.

Can PRP, Stem Cells, and Exosomes Be Combined?

Some regenerative-medicine protocols combine PRP, MSCs, or exosome-based products.

The biological rationale is that different components may influence different stages of healing or cellular signaling.

However, combining therapies does not automatically mean better results.

There is currently insufficient high-quality evidence to conclude that combinations of PRP, MSCs, and exosomes are universally superior to using an individual therapy.

Treatment plans should therefore be individualized rather than based simply on adding more products.

What Should Patients Ask Before Treatment?

Patients considering regenerative therapies should ask the clinic about:

For cell-based therapies, proper processing, characterization, storage, sterility, and clinical oversight are especially important.

COFEPRIS recognizes regenerative medicine and cellular therapies as areas requiring specific regulatory oversight in Mexico, including licensing categories for regenerative-medicine establishments and facilities handling cells and tissues. (Gobierno de México)

The Bottom Line

PRP, stem cells, and exosomes represent three different approaches to regenerative medicine.

PRP uses components from the patient's own blood and currently has the longest clinical history among these three approaches.

Mesenchymal stromal cell therapies use living cells whose biological effects appear to involve immune modulation and complex signaling between cells.

Exosomes attempt to use some of those signaling mechanisms without administering the cells themselves.

All three are active areas of research, but evidence varies substantially depending on the condition being treated.

A responsible regenerative-medicine program should evaluate the individual patient, explain the level of evidence, discuss potential risks and alternatives, and avoid promising guaranteed regeneration or cures.

Suggested meta title:

Exosomes vs PRP vs Stem Cells | Regenerative Therapy Mexico

Suggested meta description:

Compare exosomes, PRP and stem cell therapies, including how they work, potential applications, evidence, differences and important safety considerations.

How to Read Stem Cell Clinic Claims Critically

Stem cell and regenerative medicine treatments are developing rapidly, but the quality of information presented by clinics can vary widely. Some clinics communicate carefully and explain the limitations of current research, while others may use testimonials, impressive cell numbers, or broad claims that go beyond what clinical evidence currently supports.

For patients considering stem cell therapy in Mexico or elsewhere, learning how to evaluate these claims is an important part of making an informed decision.

Look Beyond Testimonials

Patient testimonials can be useful for understanding an individual experience, but they are not the same as scientific evidence.

A patient may feel better after treatment for many reasons, including natural changes in symptoms, rehabilitation, medications, lifestyle changes, or placebo effects.

The International Society for Stem Cell Research specifically warns that testimonials should not replace properly controlled clinical studies when evaluating whether a stem cell treatment is effective. (ISSCR)

A responsible clinic should be able to discuss both patient experiences and published scientific evidence.

Be Careful With Guaranteed Results

Regenerative medicine is not predictable enough to guarantee that every patient will improve.

Claims such as:

should be approached cautiously.

Stem cell research is promising, but outcomes can vary depending on the condition, severity of disease, age, health status, cell source, treatment protocol, and many other factors.

The ISSCR notes that most stem cell interventions being marketed for numerous conditions remain experimental or insufficiently proven. (ISSCR)

Ask What Type of Cells Are Actually Being Used

The term “stem cells” is very broad.

A clinic should clearly explain:

For mesenchymal stromal/stem cell treatments, products from bone marrow, adipose tissue, umbilical-cord-associated tissue, or other sources are not automatically equivalent.

The biological characteristics and manufacturing process can influence the final product.

Large Cell Numbers Do Not Automatically Mean Better Treatment

Some clinics advertise extremely large numbers of cells as if the highest number automatically represents the best treatment.

That is not necessarily true.

Cell dose is only one factor. Quality, viability, identity, sterility, source, processing methods, administration route, and the medical condition being treated may be equally or more important.

More cells do not automatically mean better results.

Patients should ask why a particular dose was selected and whether published evidence supports that dose for their condition.

Ask for Scientific Evidence for Your Specific Condition

A clinic may correctly state that stem cells have anti-inflammatory or immunomodulatory properties while still overstating what that means clinically.

Laboratory findings and animal studies are important parts of scientific research, but they do not necessarily prove that a therapy will produce the same result in humans.

When evaluating a claim, ask:

Evidence for one condition should not automatically be applied to another unrelated disease.

Understand the Difference Between “Registered,” “Approved,” and “Studied”

These terms are frequently confused.

A product being listed in a database, a laboratory being registered, or a clinical trial being listed does not automatically mean that a treatment has been proven effective.

For example, the FDA specifically warns U.S. patients that registration of a company or listing of a study on ClinicalTrials.gov does not by itself mean a regenerative medicine product is FDA-approved or legally marketed in the United States. (U.S. Food and Drug Administration)

Different countries have different regulatory systems, so patients traveling internationally should understand what the relevant authorization actually covers.

Verify Regulatory Compliance in Mexico

In Mexico, COFEPRIS regulates healthcare establishments involved in regenerative medicine and activities involving human cells and tissues.

Current COFEPRIS licensing categories include regenerative medicine establishments, stem-cell collection centers, stem-cell banks, and facilities involved in the extraction, analysis, preservation, preparation, and supply of human cells and tissues. (Gobierno de México)

Patients should ask:

Regulatory authorization of a facility does not automatically prove that every therapy offered by that facility is effective for every disease.

Be Cautious With “FDA Registered” Marketing

Some international clinics advertise that their laboratory, supplier, or product is “FDA registered.”

That phrase can easily be misunderstood.

Registration is not the same as FDA approval of a treatment.

The FDA states that, in the United States, the only FDA-approved stem cell products currently consist of certain blood-forming stem cell products used for specific hematologic disorders. The FDA also states that there are currently no FDA-approved exosome products. (U.S. Food and Drug Administration)

For international treatment, U.S. approval may not determine whether a clinic can legally operate in another country, but patients should still understand exactly what regulatory claims mean.

Ask About Risks, Not Only Benefits

Every medical procedure has potential risks.

Depending on the therapy and route of administration, potential concerns can include:

The FDA has documented reports of infections and other serious adverse events associated with improperly marketed or unapproved regenerative products. (U.S. Food and Drug Administration)

A trustworthy clinic should openly discuss risks and limitations rather than presenting treatment as completely safe.

Ask Who Will Actually Treat You

Marketing materials may emphasize the clinic's technology or laboratory while saying very little about the physician.

Patients should know:

Regenerative medicine should be approached as medical care, not simply as the purchase of a biological product.

Ask About Follow-Up Care

Treatment does not end when an infusion or injection is completed.

Before treatment, ask:

Clinics that provide structured follow-up are generally able to evaluate outcomes more responsibly than clinics that simply administer a treatment and send the patient home.

Compare the Claim With the Evidence

One useful question is:

“Does the strength of the clinic's claim match the strength of the evidence?”

If research suggests that a treatment may help some patients, marketing should not transform that into a claim that the treatment cures the disease.

Terms such as:

“may help,”
“has shown potential,”
“is being investigated,”

are very different scientifically from:

“will regenerate,”
“will reverse,”
or
“will cure.”

That distinction matters.

The Bottom Line

Stem cell therapy and regenerative medicine have genuine scientific potential, but they are also areas where marketing can sometimes move faster than clinical evidence.

Patients should evaluate more than impressive websites, testimonials, cell counts, or promises.

Look for transparency regarding:

A responsible clinic should be comfortable explaining what is known, what remains uncertain, and why a particular treatment is being recommended.

The goal should not be to find the clinic making the strongest claims.

It should be to find one willing to provide the clearest information.